Latest News
WHRY collaborator Akiko Iwasaki, PhD, joins Fiona Lowenstein, editor of “The Long COVID Survival Guide,” to discuss patients who say they’re suffering from Long COVID for as much as two years after their acute phase of the disease. Listen to their discussion as part of "Conversations on Health Care."
- November 30, 2022Source: Washington Post
Akiko Iwasaki, Yale professor of immunobiology and WHRY collaborator, is the co-author of a review article on Covid-19 related cognitive impairment. The condition has affected people with cancer and other chronic conditions for years, but long Covid is just beginning to push it into the spotlight.
- November 07, 2022
As part of our “Meet Yale Internal Medicine” series, we are featuring Benjamin Goldman-Israelow, MD, PhD, assistant professor in medicine and former ABIM Physician-Scientist Research Pathway Resident.
- November 01, 2022Source: NYU Langone Health
Infection with the pandemic virus, SARS-CoV-2, can reduce the number of bacterial species in a patient’s gut, with the lesser diversity creating space for dangerous microbes to thrive, a new study finds.
- November 01, 2022
ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) is a highly disabling, severe condition that has been largely overlooked and even questioned as an illness by physicians and biomedical researchers for decades. But now, scientists including Yale's Akiko Iwasaki and Harlan Krumholz are finding parallels between post-infection long COVID and ME/CFS.
- October 27, 2022
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
- October 27, 2022Source: YaleNews
The new “prime” and “spike” approach may help prevent breakthrough infections of vaccinated individuals by bolstering immune response within the mucosal lining of the respiratory tract, which are the first cells attacked by COVID-19.
- October 12, 2022
The annual Yale Faculty Innovation Awards are an opportunity to recognize the significant contributions of faculty investigators who launch startups in order to address global challenges.
- August 20, 2022Source: The Guardian
Unlike jabs, nasal vaccines target the respiratory tract, the body’s first line of defence against infection
- August 12, 2022Source: The New York Times
While the risks of deaths and hospitalizations from Covid-19 are substantially lower now, navigating this phase of the pandemic can be frustrating and confusing.